Relationship between Baseline and Early Changes in C-Reactive Protein and Interleukin-6 Levels and Clinical Response to Tocilizumab in Rheumatoid Arthritis

Arthritis Care and Research

Volumn 68, Issue 6, 2016, Pages 882-885

  Wang, Jianmei ^a   Devenport, Jenny ^b   Low, Jason M ^b   Yu, Dale ^c   Hitraya, Elena ^b  

^a ROCHE PRODUCTS LTD   (United Kingdom)

^b GENENTECH INC   (United States)

^c Roche Translational Clinical Research Center Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; INTERLEUKIN 6; TOCILIZUMAB; ANTIRHEUMATIC AGENT; BIOLOGICAL MARKER; IL6 PROTEIN, HUMAN; MONOCLONAL ANTIBODY;

ARTICLE; CLINICAL DISEASE ACTIVITY INDEX; CONTROLLED STUDY; CORRELATION ANALYSIS; DAS28; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; HUMAN; MAJOR CLINICAL STUDY; PREDICTION; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; TREATMENT RESPONSE; ARTHRITIS, RHEUMATOID; BLOOD; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOMARKERS; C-REACTIVE PROTEIN; HUMANS; INTERLEUKIN-6; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84969959750     PISSN: 2151464X     EISSN: 21514658     Source Type: Journal    
DOI: 10.1002/acr.22765     Document Type: Article

References (15)

1. Smolen JS, Landewe R, Breedveld FC, Dougados M, Emery P, Gaujoux-Viala C, et al., EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010; 69: 964-75.
2. Smolen JS, Aletaha D, Bijlsma JW, Breedveld FC, Boumpas D, Burmester G, et al., Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010; 69: 631-7.
3. Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, et al., 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012; 64: 625-39.
4. Robinson WH, Lindstrom TM, Cheung RK, Sokolove J., Mechanistic biomarkers for clinical decision making in rheumatic diseases. Nat Rev Rheumatol 2013; 9: 267-76.
5. Wang J, Platt A, Upmanyu R, Germer S, Lei G, Rabe C, et al., IL-6 pathway-driven investigation of response to IL-6 receptor inhibition in rheumatoid arthritis. BMJ Open 2013; 3: e003199.
6. Nishimoto N, Kishimoto T., Humanized antihuman IL-6 receptor antibody, tocilizumab. Handb Exp Pharmacol 2008; 181: 151-60.
7. Mihara M, Kasutani K, Okazaki M, Nakamura A, Kawai S, Sugimoto M, et al., Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family. Int Immunopharmacol 2005; 5: 1731-40.
8. Choy EH, Kavanaugh AF, Jones SA., The problem of choice: current biologic agents and future prospects in RA. Nat Rev Rheumatol 2013; 9: 154-63.
9. Smolen JS, Beaulieu A, Rubbert-Roth A, Ramos-Remus C, Rovensky J, Alecock E, et al., Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 2008; 371: 987-97.
10. Genovese MC, McKay JD, Nasonov EL, Mysler EF, da Silva NA, Alecock E, et al., Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the Tocilizumab in Combination With Traditional Disease-Modifying Antirheumatic Drug Therapy study. Arthritis Rheum 2008; 58: 2968-80.
11. Emery P, Keystone E, Tony HP, Cantagrel A, van Vollenhoven R, Sanchez A, et al., IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 2008; 67: 1516-23.
12. Jones G, Sebba A, Gu J, Lowenstein MB, Calvo A, Gomez-Reino JJ, et al., Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis 2010; 69: 88-96.
13. Kremer JM, Blanco R, Brzosko M, Burgos-Vargas R, Halland AM, Vernon E, et al., Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year. Arthritis Rheum 2011; 63: 609-21.
14. Smolen JS, Aletaha D., Interleukin-6 receptor inhibition with tocilizumab and attainment of disease remission in rheumatoid arthritis: the role of acute-phase reactants. Arthritis Rheum 2011; 63: 43-52.
15. Kay J, Morgacheva O, Messing SP, Kremer JM, Greenberg J, Reed GW, et al., Clinical disease activity and acute phase reactant levels are discordant among patients with active rheumatoid arthritis: acute phase reactant levels contribute separately to predicting outcome at one year. Arthritis Res Ther 2014; 16: R40.